Clinical trials: Diabetes Mellitus, Type I
Type 1 Diabetes, Dermatologic Complication
Prevention of Skin Problems With Diabetes Devices in Pediatric Patients
A Cluster-controlled Intervention Trial regarding Prevention of Dermatological Complications towards use of Continuous glucose monitoring and insulin pumps in pediatric patients with Type 1 Diabetes.
- Trial name
- NCT04258904
- Testing
- Skin Care Program
- Where
- Denmark
- Volunteers
- 236 people
- Sponsor
- Copenhagen University Hospital at Herlev
Type 1 Diabetes, Hypoglycemia
Islet Allotransplantation With Steroid Free Immunosuppression
The restoration of endogenous insulin secretion carries significant hopes for shifting the paradigm of life long exogenous insulin therapy in selected groups of patients with type 1 diabetes(T1D).
- Conditions
- Type 1 Diabetes, Hypoglycemia, Metabolic Diseases
- Trial name
- NCT00446264
- Testing
- islet transplantation, daclizumab - sirolimus - tacrolimus
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) and the pharmacokinetic (exposure of the trial drug in the body) properties of…
- Trial name
- NCT01773798
- Testing
- insulin degludec/insulin aspart 15, insulin degludec/insulin aspart, insulin degludec
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Collection of Breath and Sweat to Identify Indicators of Hypoglycemia
Subjects with type 1 diabetes will be observed in the diabetes research center clinic following a meal and an insulin injection.
- Trial name
- NCT03600116
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Diabetes Mellitus, Type 1
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- NCT05210530
- Testing
- VCTX210A unit
- Where
- 3 sites in Canada
- Volunteers
- 7 people
- Sponsor
- CRISPR Therapeutics AG
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 130 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Diseases, Heart Failure
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
A prospective, randomised, open-labelled, multi-center study. The aim of the Steno 1 study is to test multifactorial intervention in individuals with type 1 diabetes at high risk of CVD with ambitious treatment targets.
- Conditions
- Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney Failure
- Trial name
- Steno1 (NCT06082063)
- Testing
- Aspirin tablet, Semaglutide, Sotagliflozin
- Where
- 2 sites in Denmark
- Volunteers
- 2,000 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetes Mellitus, Type 1
Multicenter Study of Fulminant Type 1 Diabetes in China
This study took FT1D（fulminant type 1 diabetes） as the research object, collected the cases of FT1D patients, and described the clinical characteristics of this type of disease.
- Trial name
- NCT05593081
- Testing
- HLA
- Where
- 10 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Second Xiangya Hospital of Central South University
Type 1 Diabetes
Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D
In type 1 diabetes (T1D), immune defense cells in the body attack and destroy insulin-producing beta cells leaving affected people with a lifelong need for daily insulin injections.
- Trial name
- UST1D (NCT02117765)
- Testing
- Ustekinumab
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Type 1 Diabetes Mellitus, Peripheral Artery Disease
Clinical Features and Prevalence of Asymptomatic Peripheral Artery Disease in Patients With Type 1 Diabetes Mellitus
AIMS: Determining the clinical features and prevalence of peripheral artery disease (PAD) in asymptomatics patients with type 1 diabetes mellitus (T1DM) and checking the validity of the current recommendations regarding for PAD…
- Trial name
- NCT02910271
- Where
- Spain
- Volunteers
- 299 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Type 1 Diabetes Mellitus
Effect of Smartphone Based Telemedicine and Education in Patients With Type 1 Diabetes Mellitus
Objective: evaluation of effect of smartphone based telemedicine and education in patients with type 1 diabetes mellitus Outline: Among the patients with type 1 diabetes, the group with telemedicine and education using smartphone…
- Trial name
- NCT04721509
- Testing
- Experimental : Smartphone-based telemedicine with the app 'Songaree diabetes'
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Type 1 Diabetes Mellitus, Hypoglycemia
Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes
The primary objective of this protocol is to test the safety and efficacy of a treatment regimen consisting of maintenance therapy with efalizumab and sirolimus for 1 year followed by withdrawal of efalizumab and maintenance…
- Trial name
- RAPTIVA (NCT00672204)
- Testing
- Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 1, Diabetes Mellitus, Brittle
Diabeloop for Highly Unstable Type 1 Diabetes
Feasibility study, comparing experimental treatment (DBLHU closed-loop system) with reference treatment (Low Glucose Predictive Suspend system) in 7 patients going through a series of N-of-1 trials.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Brittle, Closed-Loop
- Trial name
- DBLHU (NCT04042207)
- Testing
- Low Glucose Predictive Suspend system, DBLHU System
- Where
- 2 sites in France
- Volunteers
- 7 people
- Sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Type 1 Diabetes
MD Logic Pump Advisor -Pediatric Study
The objective of this feasibility study is to evaluate the efficacy and safety of automated determined Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) using the MD-Logic…
- Trial name
- NCT01308164
- Testing
- MD Logic Pump Advisor
- Where
- 2 sites in Israel, Slovenia
- Volunteers
- 25 people
- Sponsor
- Rabin Medical Center
Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1
Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia…
- Conditions
- Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1
- Trial name
- NCT01781975
- Testing
- Imatinib Mesylate
- Where
- 9 sites in United States, Australia
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to compare the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of FIAsp…
- Trial name
- NCT01992588
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Metastatic Pancreatic Adenocarcinoma
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic…
- Trial name
- NCT01896869
- Testing
- Ipilimumab, Vaccine, FOLFIRINOX
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Type 1 Diabetes
To Evaluate the Bioavailability of a Tablet of AZD1656
To evaluate the bioavailability of a tablet of AZD1656.
- Trial name
- NCT00817505
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
Effectiveness of Nutrition Education in Carbohydrate Counting in People With Type 1 Diabetic
Carbohydrates are the nutrient in the diet with the greatest impact on blood glucose. Inadequate carbohydrate counts are associated with higher A1c and greater variations in postprandial blood glucose.
- Trial name
- NCT05163002
- Testing
- Nutritional education & carbohydrate counting
- Where
- Portugal
- Sponsor
- Universidade Nova de Lisboa
Type 1 Diabetes
A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus
Primary Objective: To compare exposure and activity of SAR341402 to NovoRapid® and NovoLog®. Secondary Objective: To assess the safety and tolerability of SAR341402.
- Trial name
- NCT03202875
- Testing
- SAR341402, Insulin Aspart
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.